Invesco India Pharma and Healthcare Fund Regular Growth
Invesco India Pharma and Healthcare Fund Regular Growth: NAV ₹10.61, expense ratio 3.80%. Returns vs index, rolling returns, holdings, Direct vs Regular and peers, by a SEBI Registered Research Analyst.
Key facts
- NAV
- ₹10.6100 (19 Nov 2026)
- Expense ratio
- 3.80%
- Exit load
- Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
- Minimum investment
- Rs. 1,000/-
- Category
- Sectoral Fund
- Benchmark
- BSE Healthcare TRI
- Riskometer
- Very High Risk
- Fund manager
- Mr. Aditya Khemani
- Launch date
- 18 Aug 2026
Frequently asked questions
What is the NAV of Invesco India Pharma and Healthcare Fund Regular Growth today?
The NAV of Invesco India Pharma and Healthcare Fund Regular Growth is ₹10.6100 as of 19 Nov 2026.
What is the expense ratio of Invesco India Pharma and Healthcare Fund Regular Growth?
The expense ratio (TER) is 3.80% a year. This Regular plan includes a distributor commission; the Direct plan of the same fund costs less.
Is there an exit load on Invesco India Pharma and Healthcare Fund Regular Growth?
Exit load: Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax.
How risky is Invesco India Pharma and Healthcare Fund Regular Growth?
Its SEBI riskometer is "Very High Risk" and it is in the Sectoral Fund category.
What is the benchmark of Invesco India Pharma and Healthcare Fund Regular Growth?
The benchmark is BSE Healthcare TRI. This page compares the fund with its benchmark's total-return index (TRI).
Research by iNVESTT, a SEBI Registered Research Analyst (INH000010858). Data from AMFI. Mutual fund investments are subject to market risks; past performance does not guarantee future returns.